Anitbody biotech Alder BioPharmaceuticals files for a $115 million IPO

By
A A A

Alder BioPharmaceuticals, a biotech developing antibodies to treat migraines and arthritis, filed on Wednesday with the SEC to raise up to $115 million in an initial public offering. The Bothell, WA-based company, which was founded in 2002 and booked $19 million in collaboration and licensing revenue for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol ALDR. Alder BioPharmaceuticals initially filed confidentially on February 10, 2014. Credit Suisse and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Spot the Dropout RRC
Spot the Dropout RRC                
Spot the Dropout MG
Spot the Dropout MG                 
Spot the Dropout IPC
Spot the Dropout IPC                
Spot the Dropout
Spot the Dropout                    

Stocks

Referenced

Most Active by Volume

61,142,876
  • $94.585 ▼ 2.48%
41,809,315
  • $18.1371 ▼ 0.13%
27,343,535
  • $5.225 ▼ 5.86%
24,519,657
  • $47.155 ▲ 1.87%
23,197,931
  • $35.75 ▼ 12.42%
22,353,679
  • $15.025 ▼ 1.22%
22,331,843
  • $31.5151 ▲ 0.88%
22,045,087
  • $122.12 ▼ 0.71%
As of 7/30/2015, 01:44 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com